Advanced Search
Li Tong-Du, . The Determination of ER, PR and β2-microglobulin Expression of Bladder Cancer Tissue In The Diagnosis And Prognosis Estimation of Bladder Tumor[J]. Cancer Research on Prevention and Treatment, 1996, 23(5): 265-267.
Citation: Li Tong-Du, . The Determination of ER, PR and β2-microglobulin Expression of Bladder Cancer Tissue In The Diagnosis And Prognosis Estimation of Bladder Tumor[J]. Cancer Research on Prevention and Treatment, 1996, 23(5): 265-267.

The Determination of ER, PR and β2-microglobulin Expression of Bladder Cancer Tissue In The Diagnosis And Prognosis Estimation of Bladder Tumor

More Information
  • bladder cancer patients were evaluated for β2-microglobulin expression by means of PAP method and 28 of them for also ER and PR. Result showed that ERwas positive in 10 cases(35.7%),PR positive in 8 cases (28. 6%)and β2-microglobulin positive in 15 cases (42.9%).There was a positive correlation between cancer histologic grading, clinical staging and ER, PR content, while a negative correlation existed between the former and β2-microglobulin. In 5 year follow-up study, the recurrence and mortality rate of ER(+ ),and PR (+ ) patient were higher than that of ER(-), PR(-) patient, while that of β2-microglobulin(+) patient were lower than in β2-microglobulin(-) patient. This suggests that ER and PR are present in bladder cancer tissue, they might play a role in evaluating the diagnosis and prognosis of bladder tumor.In addition,ER and PR two groups of marker opposite to each other. on the basisof and β2-microglobulin are two groups of marker opposite to each other. On the basis of this study, it stands to reason that the adjuvant hormonal therapy is tried in ER, PR positive bladder cancer patient.
  • 1 Kiang DT. et al. JAMA, 1977. 238:32.
    2 Linsalata M. Sond Gastroenterol, 1994, 29(1):67.
    3 Papac R, et al. Eur J Cancer. 1993, 29A(7):997.
    4 Schomburg A. Eur J Cancer, 1993, 29A(5):737.
    5 Marly ML, et al. Br J Dermatol, 1981. 104:507.
    6 Van dan Zugh-HF. et al. Br J Cancer. 1987. 55(2):125.
  • Related Articles

    [1]JIAO Juying, ZHOU Lei, LIN Bo, ZENG Jingyi, XU Weijie. Basic Research Progress and Prospect of Antibody-Drug Conjugate in Treatment of Pancreatic Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(9): 787-791. DOI: 10.3971/j.issn.1000-8578.2025.25.0293
    [2]YE Hunan, SHEN Yulan, LI Jiaying, ZHOU Huanhuan, ZHANG Fanrong, WANG Xiaojia. Research Advancements of Antibody-Drug Conjugates in Breast Cancer at 2024 ASCO Annual Meeting[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 185-192. DOI: 10.3971/j.issn.1000-8578.2025.24.0999
    [3]MA Yiwen, XU Junnan, SUN Tao. Research Progress in Treatment of HR-Positive/HER 2-Low Advanced Breast Cancer: Interpretation of Breast Cancer Research Hotspots in 2024 ASCO[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 98-102. DOI: 10.3971/j.issn.1000-8578.2025.24.1033
    [4]JIA Yanli, LI Xiaoyu, FAN Houwu, DUAN Wenqing, HU Lixia, ZHOU Jian, RAN Fengming, DONG Shuang. Research Progress on Mechanisms and Optimization Methods for Toxicity Induced by Antibody–Drug Conjugates[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 606-612. DOI: 10.3971/j.issn.1000-8578.2024.23.1373
    [5]HAN Jing, CHEN Yarui, WANG Song, GUAN Quanlin. Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1139-1144. DOI: 10.3971/j.issn.1000-8578.2023.23.0447
    [6]CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 855-860. DOI: 10.3971/j.issn.1000-8578.2022.21.1466
    [7]ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng. Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 703-708. DOI: 10.3971/j.issn.1000-8578.2022.22.0220
    [8]LI Zhensheng, KONG Deyou, DUAN Xuejuan, SHEN Xiaofei, SHEN Dongxing, ZHANG Jun. Effects of Whole-brain Radiotherapy Combined with Targeted Therapy on Improving Survival of HER2-positive Breast Cancer Patients with Brain Metastases[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 917-922. DOI: 10.3971/j.issn.1000-8578.2018.18.0324
    [9]Zhou Xin, Wu Chengyi. Relationship of CD44/CD24-/low with Responsiveness of Breast Cancer to Anthracycline-based Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 966-969. DOI: 10.3971/j.issn.1000-8578.2012.08.021
    [10]FU Qiang, YU Shiying, XU Sanpeng. Prognostic Correlation of HER2 Over2expressions in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(S1): 9-11. DOI: 10.3971/j.issn.1000-8578.986

Catalog

    Li Tong-Du

    1. On this Site
    2. On Google Scholar
    3. On PubMed
    Article views (1692) PDF downloads (353) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return